This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kumpf, V. J. Search for Related Content PubMed PubMed Citation Articles by Kumpf, V. J. Pubmed/NCBI databases Medline Plus Health Information Liver Diseases Social Bookmarking                         What's this?

Parenteral Nutrition-Associated Liver Disease in Adult and Pediatric Patients

Vanderbilt University Medical Center, Center for Human Nutrition, Nashville, Tennessee

Correspondence: Correspondence: Vanessa J. Kumpf, PharmD, BCNSP, Vanderbilt University Medical Center, Center for Human Nutrition, 1211 21st Ave South, Suite 514 Medical Arts Building, Nashville, TN 37232. Electronic mail may be sent to vanessa.kumpf{at}vanderbilt.edu.

There are essentially 3 types of hepatobiliary disorders associated with parenteral nutrition (PN) therapy: steatosis, cholestasis, and gallbladder sludge/stones. Reported prevalence rates of PN-associated liver disease (PNALD) vary greatly, and there are distinct differences between adult and pediatric patients. Various etiologic factors have been evaluated for significance in contributing to PNALD, including enteral feeding history, septic events, bacterial overgrowth, length of intestinal resection, and prematurity/low birth weight. Etiologic factors specifically related to the PN formulation or nutrient intake have also been evaluated, including excessive calorie intake, dextrose-to-lipid ratio, amino acid dose, taurine deficiency, IV fat emulsion (IVFE) dose, carnitine deficiency, choline deficiency, and continuous vs cyclic infusion. Minor increases in serum aminotransferase concentrations are relatively common in patients receiving PN therapy and generally require no intervention. The primary indicator of cholestasis is a serum conjugated bilirubin >2 mg/dL. When a patient receiving PN develops liver complications, it is necessary to rule out all treatable causes and minimize other risk factors. All potential hepatotoxic medications and herbal supplements should be eliminated. Modifications to the PN regimen that may be helpful include reduction of calories, reduction of IVFE dose to <1 g/kg/d, supplementation of taurine in the infant, and use of cyclic infusion. Initiation of even small amounts of enteral nutrition and use of ursodiol may be beneficial in stimulating bile flow. In the long-term PN patient with severe and progressive liver disease, intestinal or liver transplantation may be the only remaining treatment option.

Nutrition in Clinical Practice, Vol. 21, No. 3, 279-290 (2006)
DOI: 10.1177/0115426506021003279


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. S. Lee, M.-J. Kim, M.-J. Lee, C. S. Yoon, S. J. Han, J.-T. Oh, and Y. N. Park Biliary Atresia: Color Doppler US Findings in Neonates and Infants Radiology, July 1, 2009; 252(1): 282 - 289. [Abstract] [Full Text] [PDF]

				H. E. Skillman and P. E. Wischmeyer Nutrition Therapy in Critically Ill Infants and Children JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 520 - 534. [Abstract] [Full Text] [PDF]

				P. M. Sisk, C. A. Lovelady, K. J. Gruber, R. G. Dillard, and T. M. O'Shea Human Milk Consumption and Full Enteral Feeding Among Infants Who Weigh <=1250 Grams Pediatrics, June 1, 2008; 121(6): e1528 - e1533. [Abstract] [Full Text] [PDF]

				J. Siepler Principles and Strategies for Monitoring Home Parenteral Nutrition Nutr Clin Pract, June 1, 2007; 22(3): 340 - 350. [Abstract] [Full Text] [PDF]